Oncolytic viruses (OVs) offer a promising therapeutic approach to treat multiple types of cancer. In this study, we show that the manipulation of the antioxidant network via transcription factor Nrf2 augments vesicular stomatitis virus D51 (VSVD51) replication and sensitizes cancer cells to viral oncolysis. Activation of Nrf2 signaling by the antioxidant compound sulforaphane (SFN) leads to enhanced VSVD51 spread in OV-resistant cancer cells and improves the therapeutic outcome in different murine syngeneic and xenograft tumor models. Chemoresistant A549 lung cancer cells that display constitutive dominant hyperactivation of Nrf2 signaling are particularly vulnerable to VSVD51 oncolysis. Mechanistically, enhanced Nrf2 signaling stimulated viral replication in cancer cells and disrupted the type I IFN response via increased autophagy. This study reveals a previously unappreciated role for Nrf2 in the regulation of autophagy and the innate antiviral response that complements the therapeutic potential of VSVdirected oncolysis against multiple types of OV-resistant or chemoresistant cancer.
Oncolytic viruses (OVs) offer a promising therapeutic approach to treat multiple types of cancer. In this study, we show that the manipulation of the antioxidant network via transcription factor Nrf2 augments vesicular stomatitis virus D51 (VSVD51) replication and sensitizes cancer cells to viral oncolysis. Activation of Nrf2 signaling by the antioxidant compound sulforaphane (SFN) leads to enhanced VSVD51 spread in OV-resistant cancer cells and improves the therapeutic outcome in different murine syngeneic and xenograft tumor models. Chemoresistant A549 lung cancer cells that display constitutive dominant hyperactivation of Nrf2 signaling are particularly vulnerable to VSVD51 oncolysis. Mechanistically, enhanced Nrf2 signaling stimulated viral replication in cancer cells and disrupted the type I IFN response via increased autophagy. This study reveals a previously unappreciated role for Nrf2 in the regulation of autophagy and the innate antiviral response that complements the therapeutic potential of VSVdirected oncolysis against multiple types of OV-resistant or chemoresistant cancer.
INTRODUCTION
Oncolytic virotherapy is an innovative form of experimental cancer therapy that uses different virus platforms as self-amplifying biotherapeutics to selectively infect, multiply, and kill cancer cells while sparing healthy tissues. [1] [2] [3] [4] The therapeutic potential of oncolytic viruses (OVs) is highlighted by the approval of oncolytic recombinant herpes virus talimogene laherparepvec (T-VEC) to treat malignant melanoma in the United States. 5 However, variability in the clinical response to OV-based therapies and engagement of the adaptive immune response against viral rather than tumor antigens are critical roadblocks to the large-scale implementation of OVs against multiple types of cancer. 6 In addition, nearly one-third of cancer cell lines and many primary tumors maintain a residual innate immune response that renders cells resistant to infection and virus-mediated cell killing. 6 To circumvent these issues, several strategies that combine OVs with chemical agents or engineering recombinant viruses with enhanced antitumoral activity have been investigated. [7] [8] [9] [10] [11] [12] [13] [14] Vesicular stomatitis virus (VSV), an enveloped negative-sense RNA virus from the Rhabdoviridae family, is a prototypical OV that has demonstrated potent oncolytic activity in preclinical models and is being evaluated in clinical trials. 6, 15, 16 Different genetic variants of VSV have been engineered to preferentially target tumors without compromising healthy cells. For example, VSVD51 contains a deletion at methionine 51 in the matrix protein that improves its tumor specificity and impairs its replication in normal cells that have functional antiviral defenses. 17, 18 In previous studies, we demonstrated the synergistic effect of different agents, including histone deacetylase inhibitors (HDIs), as chemical switches to dampen the type I interferon (IFN) response and to increase VSVD51 replication within resistant malignancies. 10, 12 We also showed that pharmacologic disruption of the BCL-2-Beclin-1 interactions facilitated autophagy and increased the VSVD51-mediated cytolytic effect in chronic lymphocytic leukemia cells. 19 Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcriptional regulator involved in the maintenance of redox homeostasis through the control of basal and induced expression of an array of antioxidant enzymes. 20 Under homeostatic conditions, Nrf2 binds to Kelch-like ECH-associated protein 1 (Keap1), a substrate adaptor protein for the E3 ubiquitin ligase complex formed by CUL3 and RBX1 that targets Nrf2 for ubiquitination and degradation by the proteasome. During endogenous or exogenous stresses caused by either reactive oxygen species (ROS) or electrophilic chemicals, cysteine residues in Keap1 are modified, thereby inactivating its substrate adaptor function and disrupting the cycle of Nrf2 degradation. 21 This results in Nrf2 stabilization, its nuclear translocation, and the transcriptional upregulation of a multitude of antioxidant response element (ARE)-bearing genes that alleviate the stress response. 20 Induction of Nrf2 signaling by thiol-reactive small molecules has demonstrated protective efficacy in chemoprevention tumor models and clinical trials. 22 As an example, sulforaphane (SFN), an aliphatic isothiocyanate with anti-inflammatory properties known to activate Nrf2, 23, 24 has shown efficacy in men with high-grade prostatic intraepithelial neoplasia 25 and is being tested as a therapy for recurrent prostate cancer in phase II clinical trials. [26] [27] [28] Conversely, genetic analyses of human tumors have indicated that mutations and epigenetic modifications affecting the regulation of Nrf2 may cause resistance to chemotherapy through constitutive dominant hyperactivation of Nrf2 signaling. [29] [30] [31] In this study, we demonstrate that the transcription factor Nrf2 is required to direct VSVD51 replication and oncolysis in some cancer cells. A combinatorial treatment of VSVD51 and the Nrf2 inducer SFN markedly increases viral replication and oncolysis in different cancer cell lines both in vitro and in vivo. We further show that Nrf2-constitutively active chemoresistant lung cancer (A549) cells are particularly vulnerable to VSVD51-driven oncolysis and do not require SFN treatment. Mechanistically, we show that either genetic or chemical induction of Nrf2 signaling suppressed the type I IFN response via increased autophagy. By transiently silencing Nrf2 and Atg7, we demonstrate that Nrf2-mediated autophagy is critical for VSVD51 replication in chemoresistant A549 cells and bone osteosarcoma (U-2 OS) cells. Altogether, our findings highlight a previously unappreciated role for Nrf2 in the control of antiviral innate immunity and VSVD51 oncolysis.
RESULTS

SFN Enhances VSVD51 Replication and Oncolysis in PC-3 Cells
The capacity of SFN to augment VSVD51 replication was initially evaluated in human prostate cancer (PC-3) cells that display significant resistance to VSVD51-mediated cell killing.
10,12 SFN potentiated VSVD51-GFP infectivity in a dose-dependent manner, as measured by flow cytometry analysis of VSVD51-GFP + cells ( Figures 1A and   1B ). The number of VSVD51-infected cells increased from 4.2% with VSVD51 alone to 55.3% in combination with SFN (20 mM) at 48 hr (***p < 0.001) ( Figure 1B) . Similarly, the titer of VSVD51 released from infected PC-3 cells increased approximately 2 logs with SFN pretreatment ( Figure 1C ). In other human and murine cancer cell lines (DU145 and TS/A), the combination of SFN and VSVD51 also significantly increased infection when compared with VSVD51 alone ( Figure S1 ).
To evaluate the cytotoxic effect of the VSVD51+SFN combination, PC-3 tumor cells were pretreated with increasing doses of SFN and subsequently infected with VSVD51 and analyzed for viability and apoptosis at various times post-infection (p.i.) by microscopy (Figure 1D ) and flow cytometry ( Figures 1E and 1F ). Enhanced cell killing was elicited by the combinatorial treatment, but not by individual treatment, based on the proportion of annexin-V + cells and cell viability ( Figure 1D ; Figures S2A-S2C ). The 24 hr point illustrates the number of infected GFP + cells and a low level of cell death; by 48 hr, the overall number of GFP + cells remained similar, but virus-induced cell death was readily detected (Figures 1B-1F ). The VSVD51+SFN combination significantly enhanced VSVD51-mediated PC-3 cell killing (17.2% annexin-V + cells in VSVD51 versus 78.33% in VSVD51+SFN) (***p < 0.001) and decreased cell viability (80.7% in VSVD51 versus 17.2% in VSVD51+SFN) (***p < 0.001) at 72 hr p.i. (Figures 1E and  1F) . A strong statistical correlation between percentage of annexin-V + cells at 48 hr p.i. and VSVD51 infectivity at 24 hr was confirmed by the nonparametric Spearman test (r = 0.7774; p < 0.0001; n = 33) (Figure 1G ). In contrast, SFN only slightly increased VSVD51 infectivity and did not affect VSVD51 oncolysis in human non-transformed MRC-5 fibroblasts compared to PC-3 cells (Figures S3A and S3B ).
To assess the involvement of the mitochondrial pathway in mediating VSVD51-induced cell death, PC-3 cells pretreated with SFN and infected with VSVD51 were stained with MitoSOX, a probe specific for mitochondria-derived ROS. The levels of mitochondrial ROS release were statistically associated with the number of annexin-V + cells at 48 hr p.i. (r = 0.924; p < 0.0001; n = 36) ( Figure 1H ). Furthermore, and consistent with the release of ROS at the mitochondria, downstream caspases-caspase-3 and caspase-7-were activated with the combinatorial treatment, leading to poly (ADP-ribose) polymerase (PARP) cleavage ( Figure 1I ) and indicating that SFN enhanced VSVD51 replication, which preceded mitochondrialdependent apoptosis in PC-3 cells.
SFN-VSVD51 Combination Therapy Delays Tumor Progression and Improves Survival
The therapeutic effect of combined VSVD51+SFN treatment was next evaluated in vivo using both syngeneic and xenograft mouse tumor Figure 2B ), without significant weight loss ( Figure 2C ). In athymic nude mice engrafted s.c. with human PC-3 cells, a delay in tumor progression (***p < 0.001 between VSVD51 and VSVD51+SFN) and prolonged survival was also observed with co-administration of VSVD51+SFN ( Figures 2D and 2E ), without weight loss ( Figure 2F ) (median survival in days: NT = 27; SFN = 27; VSVD51 = 36; VSVD51+SFN = 48). SFN treatment alone appeared to enhance tumor growth, in agreement with the cytoprotective role of Nrf2 activation. The log rank test also indicates that the combined treatment significantly prolonged survival over no treatment (***p = 0.0005) and SFN-alone treatment (**p = 0.0036) and is approaching statistical significance over virus-alone treatment (p = 0.0565). Collectively, these data demonstrate that the VSVD51+SFN combination in vivo is significantly more effective than monotherapy.
VSVD51 Relies on Nrf2 to Replicate and Drive Oncolysis
We next sought to investigate the mechanisms of SFN-mediated enhancement of VSVD51 replication in PC-3 cells by examining the activation of Nrf2 following SFN exposure by Phosflow 
, and using an ARE promoterluciferase assay, enhanced ARE promoter activity was observed with increasing SFN concentration ( Figure 3B ). Using high-throughput qRT-PCR analysis to examine the Nrf2-dependent gene expression profile in PC-3 cells, we observed the induction of a cross section of Nrf2-regulated genes following SFN treatment, independent of VSVD51 infection ( Figure 3C ). Hmox-1 was the most highly induced Nrf2-stimulated gene after SFN treatment, as shown by an $3-fold increase in mRNA expression level in both the presence and absence of VSVD51 (***p < 0.001) ( Figure 3C ). Another known inducer of Nrf2, diethyl maleate (DEM), increased ARE promoter activity and enhanced VSVD51 infectivity in a dose-dependent manner, with a $4-fold increase in ARE activity at 100 mM (***p < 0.001) ( Fig SFN was previously shown to stimulate Nrf2 partly through intracellular ROS accumulation. 32, 33 To determine whether Nrf2 induction and VSVD51 replication were dependent on increased ROS release following SFN treatment, an oxidant-sensitive fluorescent detection probe, CM-H2DCFDA, was used to monitor ROS formation by flow cytometry. H 2 O 2 and pyocyanin were used as positive controls to validate the oxidation of the probe and the detection of ROS accumulation. Increased ROS production was not observed at 4 hr or at 24 hr after PC-3 cell stimulation with SFN ( Figure S5A ). In addition, pretreatment of cells with the ROS scavenger N-acetyl-L-cysteine (L-NAC) did not interfere with the SFN-enhanced ARE-Luc promotor activity or VSVD51 infectivity, while L-NAC was effective at reducing ROS accumulation following treatment with pyocyanin, a potent ROS inducer ( Figures S5B-S5D ). These data indicate that induction of Nrf2 using electrophilic chemical agents potentiates VSVD51-infectivity independently of intracellular ROS accumulation in PC-3 cells.
To determine whether SFN-induced VSVD51 replication required the activation of Nrf2 and the downstream antioxidant response, we examined VSVD51 replication in murine embryonic fibroblasts (MEFs) deficient for Nrf2 (Nrf2 À/À ), infected with VSVD51 in the presence or absence of SFN. Cells lacking Nrf2 had significantly lower infectivity rates when compared to wild-type (WT) MEFs after SFN treatment (**p < 0.01) ( Figure 3D ). To validate that SFN-induced VSVD51 infectivity relies on Nrf2, MEFs deficient for Keap1
(Keap1 À/À ) were also examined. VSVD51 infectivity in Keap1
MEFs had similar levels of infection to WT MEFs treated with SFN ( Figure 3D ). 34 However, VSVD51 infectivity in Keap1 À/À MEFs was enhanced by SFN treatment, suggesting that SFN has additional effects that are independent of the Nrf2/Keap1 axis.
The human A549 cell line possesses a point mutation in Keap1 that abolishes its capacity to repress Nrf2, leading to constitutive Nrf2-mediated gene expression. 31 Heme oxygenase-1 (HO-1) is one of the well-characterized Nrf2-regulated genes shown to modulate subcellular distribution and activation of Nrf2 to enhance antioxidant defenses. 35 To evaluate the importance of this axis in VSVD51
replication, chemoresistant A549 cells were transiently knocked down for Nrf2 or HO-1 using a small-interfering RNA (siRNA) approach ( Figure 3E ). A549 cells endogenously express high levels of HO-1 and were highly susceptible to VSVD51 infection ($80% infection with VSVD51 at MOI 0.01) ( Figures 3E and 3F ). A549 cells knocked down for Nrf2 or HO-1 had nearly 4-fold fewer VSVD51-GFP + cells (***p < 0.001) ( Figure 3F ) and a more than 10-fold decrease in virus titers compared to the siRNA controltreated cells (***p < 0.001) ( Figure 3G ). Nrf2 or HO-1 knockdown significantly reduced VSVD51-mediated cell killing, as shown by a $2 to 3-fold decrease in the number of annexin-V + apoptotic cells ( Figure 3H ). The knockdown of Nrf2 also significantly affected the levels of VSVD51 infection in both the presence and the absence of SFN in A549 cells ( Figure 3I ). However, as observed in the Keap1 À/À MEF cells, VSVD51 infectivity was slightly enhanced by SFN treatment, suggesting an Nrf2-independent effect of SFN in cells constitutively active for Nrf2. Finally, to broaden our observation that Nrf2 facilitates VSVD51 replication in cancer cells, U-2 OS cells were transiently knockdown for Nrf2 using an siRNA approach ( Figure 3J ). The lack of Nrf2 facilitated VSVD51 infection in U-2 OS cells, as demonstrated by a significant decrease in viral protein expression and infectivity (***p < 0.001) ( Figures 3J and 3K ). Collectively, these experiments indicate that VSVD51 relies on Nrf2 to replicate and drive oncolysis in A549 cells and U-2 OS cells.
VSVD51 Replication Is Dependent on Nrf2-Mediated Autophagy
Previous studies demonstrated that SFN can trigger autophagy in cancer cells 36 and that autophagy increases VSVD51 replication.
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The ability of SFN to induce autophagy was examined by evaluating the levels of two autophagy biomarkers: the microtubule-associated Molecular Therapy light chain 3 protein (LC3) isoform II and the autophagic cargo protein p62/SQSTM1. Immunofluorescence showed increased levels of both p62 and LC3-II and further revealed that these two proteins co-localize in the cytoplasm of SFN-treated U-2 OS cells ( Figure 4A ). The same was observed in PC-3 cells; a dose optimization established that exposure to SFN caused an increase in the lipidated form of LC3-II ( Figure 4B ), and PC-3 cells treated with the VSVD51+SFN combination generated more lipidated LC3-II than cells infected with VSVD51 alone ( Figure 4B ). Furthermore, when 3-methyladenine (3-MeA), a general phosphatidylinositol 3-kinase (PI3K) and autophagy inhibitor, was used in combination with SFN, a 3-fold reduction in the number of infected cells was observed (**p < 0.01) ( Figure 4C ), suggesting the possible involvement of autophagy in driving SFN-increased VSVD51 infectivity in PC-3 cells.
To unequivocally demonstrate the involvement of autophagy in SFN-mediated VSVD51 replication and infectivity, MEFs deficient for Atg5, an essential autophagic protein responsible for autophagosomal elongation, were used. Because both Nrf2 activation and autophagy depend on stress induction, we investigated whether Nrf2 activation regulates autophagy. Using siRNA-mediated silencing, Nrf2 expression was knocked down in A549 cells, leading to abrogation of LC3-II expression upon SFN treatment and suggesting that autophagy is partly dependent on Nrf2 expression in these cells ( Figure 4G ). These results agree with a report showing that Nrf2 regulates the gene expression of a number of proteins involved in the autophagy process. 38 The same was observed upon HO-1 knockdown in A549 cells, which suppressed SFN-induced increase in LC3-II ( Figure 4H ). The result was also observed in siRNA Nrf2 (siNrf2)-transfected U-2 OS cells, because no increase in LC3-II or p62 was detected in the absence of Nrf2 following SFN stimulation ( Figure 4I ). Collectively, these results demonstrate that VSVD51 replication is dependent on Nrf2/HO-1-mediated autophagy in different cancer cell lines.
SFN Dampens the Innate Antiviral Response
To investigate whether SFN modulates the antiviral response, HEK293T cells were transfected with the IFN-stimulated response element (ISRE)-luciferase reporter plasmid (Luc) and infected with VSVD51 in the presence or absence of increasing doses of SFN. SFN inhibited VSVD51-mediated induction of ISRE-Luc activity in a dose-dependent manner ( Figure 5A ). Using a high-throughput qPCR approach, we assessed the levels of IFN-stimulated genes (ISGs), including Ccl5, Cxcl10, Tmem173, Ddx58, and Irf7, which were all highly induced by VSV infection, whereas SFN treatment inhibited ISG expression; VSVD51-induced Ifnb1 and Il-29 mRNA were drastically inhibited by SFN by more than 50 and 500 times, respectively ( Figure 5B ). Other ISGs, such as Ifitm1, Rsad2, Mx1, Isg15, Isg56, and Oasl, were also inhibited in SFN-treated cells (Figure 5B) . Phosphorylation of IRF3 and STAT1 and the subsequent expression of ISGs such as STAT1 and STING were drastically inhibited at the protein level by the presence of SFN ( Figure 5C ). The decreased antiviral response also correlated with induced expression of HO-1 ( Figure 5C ), illustrating that increased VSVD51 infection correlates with an Nrf2-mediated inhibition of the host antiviral response. IRF3 is a critical transcription factor required for type I IFNs and ISG expression; 39 because IRF3 phosphorylation was affected by SFN treatment, we examined whether SFN also prevented IRF3 nuclear translocation and binding activity following VSVD51 infection. SFN interfered with IRF3 nuclear relocation, as denoted by the absence of IRF3 in nuclei of VSVD51+SFN-stimulated cells ( Figure 5D ). Nuclear translocation of Nrf2 was also observed in the same conditions ( Figure 5D ). As a result of IRF3 nuclear translocation impairment in SFN-treated cells, IRF3 failed to bind to its cognate binding site following SFN stimulation ( Figure S6 ).
Nrf2-Mediated Autophagy Dampens VSVD51-Induced Innate Antiviral Response
Using Sendai virus as a potent stimulator of the antiviral response, Nrf2 overexpression inhibited virus-mediated ISRE-Luc activity in a dose-dependent manner ( Figure 6A ), and knockdown of Nrf2 in A549 cells led to higher levels of P-STAT1, STAT1, and RIG-I in response to VSVD51 ( Figure 6B ). Increased expression of these antiviral markers correlated with a profound inhibition of the autophagic flux and a decreased capacity for VSVD51 to replicate in A549 cells silenced for Nrf2 ( Figure 6B ).
Our data have shown that VSVD51 replication also relies on the Nrf2-regulated gene HO-1. Using the observation that upregulation of autophagy increases VSVD51 replication, we investigated whether www.moleculartherapy.org the dampening of the antiviral response was also related to HO-1-mediated autophagy. Increased expression of HO-1 in HEK293T cells inhibited Sendai virus-mediated ISRE activity in a dose-dependent manner ( Figure 6C ). Similar to the observations in Nrf2-silenced cells, HO-1 knockdown resulted in higher levels of the antiviral effectors P-STAT1, STAT1, and RIG-I following VSVD51 infection, compared to HO-1-sufficient cells ( Figure 6D ). Stimulation of the antiviral response correlated with decreased VSVD51 replication and expression of the autophagy marker LC3-II ( Figure 6D ). Altogether, genetic inhibition of both Nrf2 and HO-1 limited autophagy in A549 cells and led to increased antiviral immunity, which further limited VSVD51 replication.
Previously, Jounai et al. 37 demonstrated, using Atg5 and Atg7 knockout (KO) MEFs, that autophagy increased virus replication by suppressing the innate antiviral response. To validate this relation- ship, Atg7 expression was silenced in A549 cells; cells knocked down for Atg7 had 2-fold fewer VSVD51-GFP + cells (***p < 0.001) ( Figure 6E ; Figure S7A ) and an $1 log decrease in virus titers compared to the siRNA control-treated cells (*p < 0.05) ( Figure S7B ). Atg7 knockdown resulted in a marked increase in P-STAT1 and RIG-I expression that correlated with >90% inhibition of VSVD51 protein expression (Figure 6F) , thus demonstrating that inhibition of autophagy also increased the antiviral response in A549 cells.
To further evaluate the effect of autophagy on VSVD51 replication and antiviral responses, U-2 OS cells were silenced for Nrf2 using siRNA. Cells lacking Nrf2 had reduced VSVD51 infectivity and replication ( Figures 6G and 6H ), which correlated with a reduction in LC3-II expression and increased STAT1 signaling, as denoted by the elevated level of STAT1 phosphorylation ( Figure 6H ). Collectively, our data demonstrate that induction of Nrf2 signaling drives autophagy to decrease innate antiviral responses and potentiate VSVD51 replication and oncolytic activity in different cancer cell models ( Figure 7) .
DISCUSSION
Many tumor cell lines and primary cancer specimens exhibit resistance to infection by OVs, partly because of persistent antiviral immunity. 6 In the effort to increase the efficacy of experimental oncolytic virotherapies, we and others have explored strategies to potentiate viral oncolysis in resistant cancer cells by combining OVs with small molecules that enhance virus replication and cell killing. [7] [8] [9] [10] [11] [12] [13] [14] In the present study, we demonstrate that the restriction to VSVD51 oncolysis can be overcome by manipulation of the oxidative stress response using the antioxidant compound SFN as an inducer of Nrf2 antioxidant activity. We demonstrated that (1) SFN selectively increased VSVD51 infectivity and cell death in cancer cells, (2) the combination of SFN and VSVD51 decreased tumor volume and increased survival in vivo, (3) VSVD51 replication was dependent on activation of the Nrf2 pathway, (4) VSVD51 replication relied on Nrf2/HO-1-mediated autophagy, and (5) activation of autophagy through the Nrf2/HO-1 axis suppressed the innate antiviral response by inhibiting IRF3 activity.
SFN is the major isothiocyanate derived from broccoli, 40 produced by the enzymatic hydrolysis of glucosinolates that are present in cruciferous plants, including broccoli sprouts. 41 Glucoraphanin, the predominant glucosinolate, is biologically inactive but is transformed into SFN by the enzymatic activity of myrosinase. SFN is rapidly absorbed in the blood and possesses antioxidant, anti-inflammatory, and cytoprotective activities. The anticancer potential of SFN has been observed in cancer cells, in carcinogen-induced and genetic animal cancer models, and in xenograft models of cancer. 42, 43 Furthermore, the combination of SFN with existing cancer chemotherapeutics was shown to increase the cytotoxic effect in vitro, 42 thus suggesting a potential therapeutic benefit in the clinical setting.
SFN treatment stimulated Nrf2 expression and dampened the antiviral innate immune response via upregulation of autophagy, thus facilitating OV-mediated cell killing both in vitro and in vivo. Mechanistically, SFN prevented IRF3 nuclear translocation and binding to its cognate binding element, thus preventing downstream STAT1 activation and the induction of ISGs. In A549 cells, the antiviral response to VSVD51 was suppressed because of the constitutive activation of Nrf2; antiviral immunity was stimulated only when Nrf2, HO-1, or Atg7 was selectively silenced using siRNA, thus reflecting the importance of the Nrf2 axis and the autophagy Furthermore, Nrf2 has been shown to regulate the expression of a number of proteins involved in macroautophagy 38 as well as ATG3, an E2-like enzyme required for the conjugation of LC3B to phosphatidylethanolamine. In addition to its role as a transcriptional regulator of the antioxidant response pathway, Nrf2 positively regulated autophagy and is an essential component of regulatory networks that respond to different types of stress, including protein aggregation, nutrient deficiency, and viral infection. Although previously reported that SFN action is dependent on ROS production in PC-3 cells, 44 we demonstrated that SFN alone did not stimulate ROS accumulation and the effects of SFN on Nrf2 activity and VSVD51-induced infectivity were independent of ROS. Activation of Nrf2 by SFN was previously shown to be independent of ROS, because SFN directly binds to cysteine residues within the Nrf2 repressor Keap1 in vitro, 34, 45 with C151 serving as the main sensor cysteine. 46, 47 The Nrf2-regulated gene HO-1 was one of the Nrf2-regulated activities responsible for the induction of autophagy. It is possible that HO-1 activates autophagy via the ataxia telangiectasia mutated (ATM) protein, which triggers autophagy by inhibiting mTORC1. 48 Nrf2 positively regulates ATM during cell stress, and ATM is activated by the accumulation of carbon monoxide, a product of HO-1 catalysis. 49 Thus, HO-1 may activate autophagy through the production of carbon monoxide, which then activates ATM, inhibits mTORC1, and facilitates autophagy. In support of this idea, blockade of type I IFN production by rapamycin inhibited mTORC1 and potentiated the oncolytic activity of VSVD51. 50 Consistent with the preceding idea, the mTOR pathway was inhibited following SFN treatment in PC-3 cells (D.O., unpublished data), and SFN was shown to induce autophagy through the inhibition of mechanistic target of rapamycin (mTOR) in primary murine hepatocytes. 51 Because inhibition of mTOR is crucial to the potentiation of VSVD51 oncolysis, 50 further studies are required to investigate the relationship between mTOR signaling and stimulation of VSVD51 replication by SFN.
In addition to suppression of the innate antiviral response, stimulation of the adaptive immune response by OV infection is an essential part of a curative response. 4, [52] [53] [54] Cancer cells reside in the complex host-tumor microenvironment and have evolved to suppress signaling to the adaptive immune system to evade T cell-mediated detection and destruction. 3, 4, 54 By dampening the innate antiviral response using oncolytic adjuvants, VSVD51 and other OVs replicate more robustly within the tumor mass, increase inflammation in the tumor bed, and facilitate an adaptive T cell-mediated response against tumor antigens via cross presentation. 52, [54] [55] [56] Although more detailed mechanistic studies are required to investigate the effects of SFN in vivo, we speculate that SFN enhances the therapeutic effect of VSVD51 in tumor models by a similar mechanism. We also speculate that the small tumor volumes associated with the TS/A model in BALB/c mice correlated with the immunocompetent environment that targeted the TS/A tumor cells, in contrast to the immunodeficient environment associated with the PC-3-nude mouse model. Our results, along with numerous other studies, demonstrate that combinatorial oncolytic virotherapy culminates in multiple mechanisms of tumor killing: direct virus-mediated cell death, stimulation of inflammation within the tumor, and induction of a targeted adaptive immune response. 2, 54, 57 The cancer cell line most susceptible to VSVD51-mediated cell killing was the human lung epithelial A549 line that harbors a point mutation inactivating Keap1, thus increasing Nrf2 nuclear translocation and transcriptional activity. 31 High levels of Nrf2 correlate with poor prognosis, and often patients bearing tumors with high amounts of nuclear Nrf2 are resistant to chemotherapy and radiation therapy. 31 An OV approach could be advantageous in patients with chemo-and radio-resistant Nrf2-associated tumors, because OV activity may be preferentially increased in this subset of tumors. Our studies are being directed toward establishing correlations among Nrf2 activation, antiviral suppression, and susceptibility to OV replication in tumors bearing mutations of the Nrf2/Keap1 axis. With regard to the transition of this and related combinatorial strategies to the clinic, both OVs and SFN are being evaluated as monotherapies in clinical trials. SFN, at concentrations that are achievable in vivo, has been shown to be non-toxic to healthy cells, 26,58,59 and mice exhibited no visible adverse effects to SFN; likewise, OV administration is well tolerated in multiple clinical trials. 2, 57 Although we demonstrated that the SFN-mediated inhibition of the antiviral responses and enhanced OV efficacy is tumor cell specific, investigation of this promising combination approach could facilitate clinical implementation of OVs as therapeutic agents for the treatment of a variety of cancer types.
Collectively, our data demonstrate that SFN stimulates an Nrf2-regulated, multi-functional, transcriptional network that, in the context of virus infection, leads to the induction of autophagy, suppression of the IFN-mediated antiviral response, and subsequent enhancement of VSVD51 replication and tumor cell death. Furthermore, our findings reveal a previously unappreciated role for Nrf2 in controlling VSVD51 replication that could ultimately provide to patients with Nrf2-associated tumors an alternative form of immune-based therapy.
MATERIALS AND METHODS
Cell Lines and Culture Conditions
Human PC-3 and A549 cell lines were obtained from the American Type Culture Collection (ATCC). PC-3 and A549 cells were cultured in F12K medium (Wisent) supplemented with 10% fetal bovine serum (FBS, Wisent) and 1% antibiotics (Sigma-Aldrich). HEK293T cells were also obtained from ATCC and cultured in DMEM (Wisent) supplemented with 10% FBS and 1% antibiotics. TS/A cells (murine mammary adenocarcinoma) cultured in DMEM MEFs were obtained from Dr. Masayuki Yamamoto (Tohoku University). MEF cell lines were generated from day 13.5 embryos of WT, Nrf2 À/À , and Keap1 À/À C57BL/6 mice 60,61 and were cultured as previously described. 62 WT Atg5 (Atg5 +/+ ) and Atg5-knockout (Atg5
MEFs were a gift from Dr. Yu-Ying He (University of Chicago) and were originally produced by Dr. Noboru Mizushima. 63 MEF cells were cultured in DMEM supplemented with 10% FBS and 1% antibiotics. All cell lines were incubated at 37 C in a humidified atmosphere of 5% CO 2 and 95% air.
Drugs and Cytokine
SFN and DEM were purchased from Santa Cruz Biotechnology and dissolved in DMSO and 95% ethanol, respectively. 3-MeA, L-NAC, pyocyanin, and H 2 O 2 were purchased from Sigma-Aldrich. The pH of the L-NAC solution was adjusted to 7. IFN-a2b was obtained from Merck.
VSV Production, Quantification, and Infection VSVD51-expressing GFP is a recombinant derivative of the VSV Indiana serotype described previously. 18 The virus was provided by Drs. John Bell and David Stojdl (Ottawa Health Research Institute). VSVD51 was propagated on Vero cells, and virus titers were quantified by a standard plaque assay method on Vero cells as described previously.
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In Vitro Treatment with Drugs and Infection with VSVD51
Cancer cell lines or MEFs were pretreated for 24 hr with SFN. Subsequently, cells were infected at indicated MOIs with VSVD51 for the indicated periods. The cells were imaged with the ZOE Fluorescent Cell Imager (Bio-Rad). The percentage of cells infected with VSVD51 was determined based on GFP expression using a BD LSR Fortessa cell analyzer (Becton Dickinson); calculations, as well as population analyses, were done using FACSDiva.
Flow Cytometry Cell Viability and Apoptosis Analyses
Cell viability and apoptosis were assessed as previously reported 64 by flow cytometry and were based on the measurement of phosphatidylserine externalization at the cell surface using a specific annexin-V antibody.
Total and Mitochondrial ROS Production
Total ROS and mitochondrial-dependent ROS using CM-H2DCFDA (1 mM) and MitoSOX Red Mitochondrial Superoxide Indicator (0.5 mM, Life Technologies) were evaluated by flow cytometry. Following SFN treatment and/or VSVD51 infection, cells were washed in PBS before incubation with the different probes for 30 min at 37 C. After incubation, cells were washed twice in PBS before fluorescence-activated cell sorting (FACS) analysis.
Nrf2 Phosflow
Phospho-Nrf2 staining was performed in a 96-well plate format. Cells were resuspended in 100 mL of PBS and fixed with the same volume of prewarmed Fix Buffer I (BD Biosciences) for 10 min at 37 C. Cells were pelleted down by centrifugation and resuspended in 200 mL ice-cold Perm Buffer III (BD Biosciences) for 20 min at 4 C. Cells were then washed three times with 200 mL of PBS containing 5% FBS and incubated for 30 min on ice in PBS containing 2% FBS. Cells were pelleted down by centrifugation and stained in 100 mL PBS containing 2% FBS with a rabbit monoclonal phospho-S40-Nrf2 antibody (ab76026, Abcam) for 30 min at room temperature (RT). Cells were washed twice in staining buffer and stained with an Alexa Fluor 488 (AF488)-conjugated goat antirabbit secondary antibody (ab150077, Abcam) for an extra 30 min at RT. After two more washes using the staining buffer, cells were analyzed by flow cytometry.
Protein Extraction and Immunoblot Analysis
Cells were washed twice with ice-cold PBS and lysed in ice-cold buffer containing 10% glycerol, 20 mM Tris-HCl (pH 7.5), 1% Triton X-100, 5 mM NaF, 40 mM b-glycerophosphate, 1 mM Na 3 VO 4 , 150 mM NaCl, 1 mM PMSF, 1 mM DTT, 10 mM NEM, and protease inhibitor cocktail (Sigma-Aldrich). Lysed extracts were kept on ice for 30 min and centrifuged at 10,000 Â g for 15 min at 4 C. Then, 20-40 mg of clarified whole-cell lysates were separated by SDS-PAGE on 4%-12% precast gradient gels (Bio-Rad). Proteins were electrophoretically transferred to a nitrocellulose membrane (0.45 mM, Bio-Rad) for 1 hr at 100 V in a buffer containing 30 
RNA Extraction and High-Throughput qPCR Assay
RNA extraction and high-throughput qPCR BioMark assay were performed as described previously. 65, 66 The sequences of primers used, as well as their complementary probes, are available upon request or can be seen in Olagnier et al. 66 Nuclear Protein Extraction and IRF3 DNA-Binding Activity Nuclear and cytoplasmic proteins were isolated using the following protocol. Cells were lysed in a 400 mL solution containing 10 mM Tris, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 0.1% protease inhibitor, 1 mM DTT, 1 mM PMSF, 10 mM sodium orthovanadate, 20 mM NaF, and 40 mM b-glycerophosphate at 4 C. After 15 min, 25 mL of 10% NP40 was added, and the solution was centrifuged at maximum speed for 5 min. The supernatant was collected and kept as the cytoplasmic fraction. The pellet was washed once more in the previously mentioned lysis solution and then lysed with 25 mL of another lysis solution containing 20 mM Tris, 400 nM NaCl, 1 mM EDTA, 1 mM EGTA, 0.1% protease inhibitor, 1 mM PMSF, and 40 mM b-glycerophosphate at 4 C while vortexing. After 1 hr, the solution was centrifuged at max speed for 15 min, and the supernatant was kept as the nuclear extract. At least 10 mg of protein were loaded per gel. IRF3 TransAM ELISA kit (Active Motif) was used to evaluate IRF3 DNA-binding activity as per manufacturer's recommendations.
Plasmid Constructs
Plasmids encoding ISRE-Luc and pRLTK have been described previously. 67, 68 The pP-ARE-Luciferase reporter plasmid bearing the ARE of human Nqo1 gene was a gift from Dr. Alexander Ivanov (Engelhardt Institute of Molecular Biology, Russian Academy of Sciences). 69 The Nrf2 overexpression plasmid was provided by Dr. Volker Blank (Lady Davis Institute) and was described previously. 70 The HO-1 overexpression plasmid was provided by Dr. Hyman Schipper (Lady Davis Institute) and was described previously. 71 
Luciferase Assay
For ISRE-Luc assays, experiments were performed as previously reported using the calcium phosphate transfection method. 68 For ARE luciferase assays, HEK293T cells were transfected with 50 ng of pRLTK reporter plasmid, 100 ng of pP-ARE-Luc reporter, and increasing doses of the expression plasmid encoding for Nrf2 or HO-1, along with the appropriate amount of empty vector, by the calcium phosphate transfection method. After 24 hr of transfection, luciferase activity was measured with a dual-luciferase reporter assay and a GloMax 20/20 luminometer according to the manufacturer's recommendations (Promega).
Transfection and siRNA
For siRNA experiments, A549 cells were transfected with 75 pmol of human Nrf2 (sc-37030), HO-1 (sc-35554), Atg7 (sc-41447), or control siRNA (sc-37007) diluted in Opti-MEM (Thermo Scientific) and using Lipofectamine RNAi Max as per manufacturer's instructions. A549 cells were incubated for 48 hr in the presence of the siRNA before being challenged with VSVD51. C prewarmed PBS, fixed with ice-cold methanol (À20 C) for 15 min, and permeabilized with 0.1% Triton X-100 in PBS (PBS-Tx) for a further 15 min. Next, the cells were placed in blocking solution (3% normal donkey serum in PBS-Tx) for 30 min at RT, after which they were incubated for 1-1.5 hr at RT with mouse anti-p62 (1:400, Abcam) or rabbit anti-LC3BII (1:200, Cell Signal) antibodies diluted in the blocking solution. After three washes every 5 min using PBS-Tx, the cells were incubated for 1 hr in the dark with Alexa Fluor 594 nm fluorophore-conjugated antirabbit (1:400) and Alexa Fluor 680 nm fluorophore-conjugated antimouse (1:400) secondary antibodies (Jackson ImmunoResearch) diluted in the blocking solution. After washing three times every 5 min using PBS-Tx and a further 5 min wash with PBS, the cells were incubated with DAPI (dissolved in PBS at a final concentration of 2.5 mg/mL) for 5 min at RT in the dark. The cells were quickly washed three times with PBS, mounted onto frosted glass slides (VWR) using 30 mL of ProLong gold antifade mounting medium (Invitrogen), and left to cure overnight at RT. On the following day, the cells were imaged using widefield microscope (Deltavision Elite, GE Healthcare). The data shown represent the maximum intensity projection of 25 optical sections obtained with 0.2 mm thickness per section.
In Vivo Tumor Models TS/A Model 8-week-old-female BALB/c mice obtained from Charles River Laboratories were injected s.c. with 3 Â 10 5 TS/A cells suspended in 100 mL PBS (n = 7 animals per group). Approximately 7 days later, when tumors became palpable (100-150 mm 3 ), tumors were injected with 2 Â 10 7 PFU of VSVD51-GFP (in 75 mL of PBS) on day 0 and day 4. SFN at 10 mg/kg was administered i.p. 1 day before the first VSVD51 injection and then on days 1, 4, and 6 following the first VSVD51 administration. Tumors sizes were measured at the indicated time points using an electronic caliper, and tumor volume was calculated as length Â (width) 2 /2. To account for variable tumor size at the beginning of the experiment, tumor volume was normalized to its initial volume on day 0 and presented as a percentage. For survival studies, mice were euthanized when tumors had reached 2,000 mm 3 or presented evidence of necrosis or sepsis at the tumor site. Log rank (Mantel-Cox) tests were performed on Kaplan-Meier survival graphs using Prism 5 (GraphPad). To assess for the safety of the combinatorial treatment, mice were weighed every 2 days until day 8.
PC-3 Model
10-week-old-male athymic nude mice obtained from Charles River Laboratories were injected s.c. with 5 Â 10 6 human PC-3 cells (n = 7 animals per group). Four weeks later, when tumors reached 100-150 mm 3 , mice were treated intratumorally ( i.t.) with 
Statistical Analysis
Values were expressed as the mean ± SEM. Graphs and statistics were computed using Microsoft Excel or GraphPad Prism 5. An unpaired, two-tailed Student's t test was used to determine significance of the difference between the control and each experimental condition. The p values of less than 0.05 were considered statistically significant: ***p < 0.001, **p < 0.01, and *p < 0.05. The log rank (Mantel-Cox) test was used to determine significant differences in plots for mice survival studies. A two-way ANOVA analysis was used to calculate significant differences in plots for tumor growth studies. 
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